A Trial for Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome

Trial Profile

A Trial for Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 May 2017

At a glance

  • Drugs Ganetespib (Primary) ; Gemtuzumab ozogamicin (Primary) ; Quizartinib (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AML-18; AML18
  • Most Recent Events

    • 13 Jul 2016 This trial was suspended in Denmark, according to European Clinical Trials Database.
    • 03 Mar 2016 Accrual to date is 17% according to United Kingdom Clinical Research Network.
    • 02 Dec 2015 Accrual to date is 12% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top